Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center

About this trial

This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Outpatients with MPE undergoing IPC placement

Sufficient mental capacity to provide informed consent and answer Short-Form Six-Dimension health index (SF-6D) and Borg score questions

Inpatients that are expected to be discharged within 5 days of receiving an indwelling pleural catheter

Disqualifiers

Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)

Inability or unwillingness to give informed consent

Inability to perform phone call and clinical follow-up at MD Anderson Cancer Center (MDACC)

Pregnancy

Trial population

Outpatients with MPE undergoing IPC placement

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Doxycycline

    Drug

    Receive via IPC

  • Indwelling Catheter

    Device

    Receive IPC

  • Quality-of-Life Assessment

    Procedure/Surgery

    Ancillary studies

  • Questionnaire Administration

    Other intervention

    Ancillary studies

  • Survey Administration

    Other intervention

    Ancillary studies

Treatment groups

208 Participants
are divided into 2 treatment groups
Group A: Group 2 (IPC alone)4 interventions
Group B: Group I (IPC, doxycycline)5 interventions

Trial outcomes

Primary outcomes

1

Time to pleural catheter removal

This outcome will be analyzed by cause-specific hazard Cox model with treatment group as a covariate. Whenever a catheter is removed, the cause for removal will be documented. For the analysis, causes will include removal due to decreased drainage (i.e., as per plan) as well as removal due to complications (e.g. infection, empyema, refractory pain) or other reasons (e.g. catheter plugged but no complication to the patient, patient preference without a complication). We will also analyze time to catheter removal for any cause and conduct pre-specified secondary analyses to evaluate the effect of fluid drainage amount (i.e., how much was being put out from the indwelling pleural catheter (IPC) the day of IPC placement and on the day of doxycycline instillation) and size of residual effusion as assessed by chest x-ray (CXR) (on day of IPC placement and day of doxycycline instillation) on time to catheter removal.

Time frame
Up to 1 year

Secondary outcomes

1

Recurrence of effusion requiring drainage after IPC

Time frame
Up to 1 year
2

Indwelling pleural catheters (IPC) complications

Time frame
Up to 1 year
3

Quality-adjusted survival measured using Short-Form Six-Dimension health index (SF-6D)

Will use the Kaplan-Meier product-limit method to estimate median quality-adjusted life years (QALYs) following IPC placement.

Time frame
Baseline up to 1 year
4

Change in dyspnea using Borg score

Will use paired t-test to compare baseline and 1 month Borg scores and utilities. A generalized linear model will be used to evaluate whether other variables have any impact on the pairwise differences between baseline and 1 month.

Time frame
Baseline up to 1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

M.D. Anderson Cancer Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator